Form 4: ResMed Director Christopher DelOrefice Acquires Shares Through Restricted Stock Units

ResMed director Christopher DelOrefice acquired 1,083 shares of common stock through the vesting of restricted stock units.

Summary

• Christopher DelOrefice, a director at ResMed Inc., acquired 1,083 shares of ResMed common stock on November 20, 2024.
• The shares were acquired through the vesting of restricted stock units (RSUs).
• These RSUs will cliff vest on the earlier of November 11, 2025, or the annual shareholder's meeting in the year following the grant date.
• Following the transaction, Mr. DelOrefice beneficially owns 1,350 shares of ResMed common stock.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to executive compensation, which is generally viewed neutrally to slightly positive as it aligns management interests with shareholders.

Positives

• The acquisition of shares by a director can be seen as a positive sign of confidence in the company's future.

Industry Context

This is a routine filing related to executive compensation and is common practice for publicly traded companies.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) as part of executive compensation is a common practice among publicly traded companies, including those in the medical device industry.
• Companies like Medtronic, Stryker, and Boston Scientific also use RSUs as part of their compensation packages for directors and executives.
• The vesting schedule of the RSUs, with a cliff vesting date, is also a standard practice to incentivize long-term commitment and performance.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns the director's interests with the company's performance.

Key Dates

Keywords

ResMed, Director, Christopher DelOrefice, Restricted Stock Units, RSU, Share Acquisition, Beneficial Ownership, SEC Form 4